Scientists test powerful new drug cocktail for tough blood cancers
NCT ID NCT05455294
Summary
This early-stage study aims to find a safe dose for a new combination of three drugs (navitoclax, venetoclax, and decitabine) to treat aggressive forms of blood and bone marrow cancers. It will enroll about 36 adults with specific high-risk conditions like acute myeloid leukemia or myelofibrosis who have limited treatment options. The main goal is to determine how much of the drug combination can be given safely before testing its effectiveness in later studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.